We would love to hear your thoughts about our site and services, please take our survey here.
I could be explaining wrong? I bought in at around 0.35 and sold out at a loss. Over the last couple of years the sp has gone further down and feel like I should have bought in when I had funds that I don’t have now!?
I’m a PI and not very experienced with the markets. I’ve won some and lost on a fairly equal balance.
I’ve been watching ORCP for 3 years and dabbled in and out. However, I’ve just come back in and won’t be touching my shares this time. There does feel like an air of positivity here. Good luck to all LTH’s I wish I had averaged down instead of selling out previously.
Thanks for responding Goodlife,
I do see the frustration. I also see that some of the most successful businesses in the world often have terrible comms :-)
Let’s hope the same applies for Syme
I’ve had Syme on my watchlist for a few years, however when it comes to investing I’m a complete novice.
I decided to invest in Syme and maybe I’m wrong but I do think it has great potential.
Just a couple of questions to LTH’s (and to anyone who wants to deramp I do take the time to look at your profiles!)
Why was the Q & A so important? Was it such a disaster? Isn’t a Q & A just about where they are now? Why did so many people on here think something new was going to said?
Isn’t the rise in share price about the recent RNS’? And how the company are moving forward?
If the Q & A was presented with current facts, albeit the comms/presenters were not great what is the problem?
What has changed from last week and what is expected over coming months?
I can see this share is traded a lot and some people are clever enough to enter and exit with fantastic profit, however I have come on board as a medium/long investor for the future not a day/week gamble.
Anyway I don’t often write on boards, I just read and make my own mind up. Yes there seems to be a lot of rampers/derampers on here, I may be a fool but I’m holding and waiting for next news expected and beyond.
Good luck all,
I simply like this company and will stick
Just because a few people are taking profit others panic sell! We are on cusp of further good news! Makes sense to profit take, however you’ll always get the panickers, shame as others lurking to get in cheap.
Are so desperate to get in cheaper! So funny
Great news, you don’t bring on a firm like thyssenkrupp Uhde unless you’re thinking big!
Someone or something is trying to get in a little cheaper! IMO
Depending on what other companies are at the same address?
.3 won’t happen, watch this space!
Hi Kettle,
Can we join via email only? With just a screenshot of shares?
833,000, emailed thank you
So..we have had time to digest…
You either leave or stay on, I’m definitely staying, I’ve lost a fair bit on paper, and this being aim and I walked in with my eyes open to the gamble, I’m liking what I see in this next chapter.
Has anyone read up about some of the new appointed directors?
Iain Ross has some iron in his fist.
Glass half full..
Bi-Cygni Sounds like a fantastic therapeutic.
Well done Tiffany Thorn! Bring my money back!!
https://www.google.co.uk/amp/s/www.bbc.com/news/science-environment-32026636.amp
Only so I stop looking on this site for life and I definitely stop reading ADVN site which is making me go cross eyed!! Haha
So..just to be clear, motif Inc has been bought by Tamarack (Orange) which Iclaprim is now associated with. If Iclaprim gets sold after paying the debt owed, morltif plc will receive 90% of what’s left over.
Motif plc is still going through RTO with a UK based company.
Sounds good to me if that’s correct?
I think we are holding our breath for the next chapter of news! ??
From the half year report....The Company no longer has control of Motif BioSciences Inc. but does retain a contractual interest in any upside in consideration, above what is owed to Hercules Capital Inc. ("Hercules"), at the time of monetisation, should the iclaprim asset be monetised by Hercules. To date, the Subsidiary and Hercules have been unsuccessful in monetising the iclaprim asset, and it is not clear when or if they will be able to do so. If there is a monetisation of the iclaprim asset, it is also unclear if there would be any residual available to the Company's shareholders above what Hercules will be owed at that time.